Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
475
mi
from 02139
Richmond, VA
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
475
mi
from 02139
Richmond, VA
Click here to add this to my saved trials
Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects
Study to Evaluate the Effect of BMS-791325 on the Pharmacokinetics of the CYP3A4 Probe Midazolam Administered Orally in Healthy Subjects
Status: Enrolling
Updated:  6/7/2013
Wcct Global, Llc
2585
mi
from 02139
Cypress, CA
Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects
Study to Evaluate the Effect of BMS-791325 on the Pharmacokinetics of the CYP3A4 Probe Midazolam Administered Orally in Healthy Subjects
Status: Enrolling
Updated: 6/7/2013
Wcct Global, Llc
2585
mi
from 02139
Cypress, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
2594
mi
from 02139
Los Angeles, CA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
2594
mi
from 02139
Los Angeles, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
2567
mi
from 02139
San Diego, CA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
2567
mi
from 02139
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
2561
mi
from 02139
San Marcos, CA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
2561
mi
from 02139
San Marcos, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
1172
mi
from 02139
New Port Richey, FL
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
1172
mi
from 02139
New Port Richey, FL
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
1119
mi
from 02139
Orlando, FL
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
1119
mi
from 02139
Orlando, FL
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
1180
mi
from 02139
Tampa, FL
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
1180
mi
from 02139
Tampa, FL
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
934
mi
from 02139
Atlanta, GA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
934
mi
from 02139
Atlanta, GA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
1356
mi
from 02139
New Orleans, LA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
1356
mi
from 02139
New Orleans, LA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
172
mi
from 02139
Manhasset, NY
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
172
mi
from 02139
Manhasset, NY
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
265
mi
from 02139
Philadelphia, PA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
265
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
270
mi
from 02139
Philadelphia, PA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
270
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
1123
mi
from 02139
Germantown, TN
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
1123
mi
from 02139
Germantown, TN
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
1548
mi
from 02139
Dallas, TX
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
1548
mi
from 02139
Dallas, TX
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
2092
mi
from 02139
Murray, UT
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
2092
mi
from 02139
Murray, UT
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
180
mi
from 02139
Burlington, VT
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
180
mi
from 02139
Burlington, VT
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
472
mi
from 02139
Richmond, VA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
472
mi
from 02139
Richmond, VA
Click here to add this to my saved trials
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated:  7/9/2013
Borland-Grooover Clinic
1018
mi
from 02139
Jacksonville, FL
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated: 7/9/2013
Borland-Grooover Clinic
1018
mi
from 02139
Jacksonville, FL
Click here to add this to my saved trials
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated:  7/9/2013
Venture Research Institute
1247
mi
from 02139
Miami, FL
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated: 7/9/2013
Venture Research Institute
1247
mi
from 02139
Miami, FL
Click here to add this to my saved trials
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated:  7/9/2013
Orlando Immunology Center
1112
mi
from 02139
Orlando, FL
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated: 7/9/2013
Orlando Immunology Center
1112
mi
from 02139
Orlando, FL
Click here to add this to my saved trials
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated:  7/9/2013
MetroWest Medical Center
17
mi
from 02139
Framingham, MA
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated: 7/9/2013
MetroWest Medical Center
17
mi
from 02139
Framingham, MA
Click here to add this to my saved trials
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated:  7/9/2013
UMASS Memorial Medical Center
35
mi
from 02139
Worcester, MA
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated: 7/9/2013
UMASS Memorial Medical Center
35
mi
from 02139
Worcester, MA
Click here to add this to my saved trials
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated:  7/9/2013
Cumberland Research Associates
660
mi
from 02139
Fayetteville, NC
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated: 7/9/2013
Cumberland Research Associates
660
mi
from 02139
Fayetteville, NC
Click here to add this to my saved trials
A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
Status: Enrolling
Updated:  7/17/2013
Clinical Research Facility
1244
mi
from 02139
Fort Myers, FL
A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
Status: Enrolling
Updated: 7/17/2013
Clinical Research Facility
1244
mi
from 02139
Fort Myers, FL
Click here to add this to my saved trials
A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
Status: Enrolling
Updated:  7/17/2013
Clinical Research Facility
1763
mi
from 02139
San Antonio, TX
A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
Status: Enrolling
Updated: 7/17/2013
Clinical Research Facility
1763
mi
from 02139
San Antonio, TX
Click here to add this to my saved trials
Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation
Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation
Status: Enrolling
Updated:  7/23/2013
Indiana University School of Medicine - IUHealth-University Hospital
803
mi
from 02139
Indianapolis, IN
Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation
Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation
Status: Enrolling
Updated: 7/23/2013
Indiana University School of Medicine - IUHealth-University Hospital
803
mi
from 02139
Indianapolis, IN
Click here to add this to my saved trials
To Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  8/6/2013
University of Miami, Division of Clinical Pharmacology
1256
mi
from 02139
Miami, FL
To Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 8/6/2013
University of Miami, Division of Clinical Pharmacology
1256
mi
from 02139
Miami, FL
Click here to add this to my saved trials
To Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  8/6/2013
Orlando Clinical Research Center
1117
mi
from 02139
Orlando, FL
To Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 8/6/2013
Orlando Clinical Research Center
1117
mi
from 02139
Orlando, FL
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Mayo Clinic Hospital
2292
mi
from 02139
Phoenix, AZ
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Mayo Clinic Hospital
2292
mi
from 02139
Phoenix, AZ
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
West Coast Clinical Trials, LLC
2585
mi
from 02139
Cypress, CA
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
West Coast Clinical Trials, LLC
2585
mi
from 02139
Cypress, CA
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
University of California Antiviral Research Center (AVRC)
2576
mi
from 02139
San Diego, CA
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
University of California Antiviral Research Center (AVRC)
2576
mi
from 02139
San Diego, CA
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Indiana University Medical Center
802
mi
from 02139
Indianapolis, IN
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Indiana University Medical Center
802
mi
from 02139
Indianapolis, IN
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Tulane University Health Sciences Center
1356
mi
from 02139
New Orleans, LA
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Tulane University Health Sciences Center
1356
mi
from 02139
New Orleans, LA
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
National Institute of Allergy and Infectious Diseases
391
mi
from 02139
Bethesda, MD
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
National Institute of Allergy and Infectious Diseases
391
mi
from 02139
Bethesda, MD
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Beth Israel Deaconess Medical Center
2
mi
from 02139
Boston, MA
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Beth Israel Deaconess Medical Center
2
mi
from 02139
Boston, MA
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Henry Ford Hospital
610
mi
from 02139
Detroit, MI
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Henry Ford Hospital
610
mi
from 02139
Detroit, MI
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Scientella, LLC
1044
mi
from 02139
Creve Coeur, MO
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Scientella, LLC
1044
mi
from 02139
Creve Coeur, MO
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Kansas City Gastroenterology & Hepatology
1248
mi
from 02139
Kansas City, MO
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Kansas City Gastroenterology & Hepatology
1248
mi
from 02139
Kansas City, MO
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Weill Medical College of Cornell University
184
mi
from 02139
New York, NY
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Weill Medical College of Cornell University
184
mi
from 02139
New York, NY
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
University Hospitals of Cleveland
542
mi
from 02139
Cleveland, OH
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
University Hospitals of Cleveland
542
mi
from 02139
Cleveland, OH
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
CRI Worldwide, LLC
271
mi
from 02139
Philadelphia, PA
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
CRI Worldwide, LLC
271
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Baylor College of Medicine
1601
mi
from 02139
Houston, TX
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Baylor College of Medicine
1601
mi
from 02139
Houston, TX
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
University of Utah
2088
mi
from 02139
Salt Lake City, UT
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
University of Utah
2088
mi
from 02139
Salt Lake City, UT
Click here to add this to my saved trials
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Status: Enrolling
Updated:  8/8/2013
Axis Clinical Trials
2593
mi
from 02139
Los Angeles, CA
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Status: Enrolling
Updated: 8/8/2013
Axis Clinical Trials
2593
mi
from 02139
Los Angeles, CA
Click here to add this to my saved trials
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Status: Enrolling
Updated:  8/8/2013
Prism Research
1115
mi
from 02139
St. Paul, MN
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Status: Enrolling
Updated: 8/8/2013
Prism Research
1115
mi
from 02139
St. Paul, MN
Click here to add this to my saved trials
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Status: Enrolling
Updated:  8/8/2013
New Orleans Center for Clinical Research - Knoxville
815
mi
from 02139
Knoxville, TN
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Status: Enrolling
Updated: 8/8/2013
New Orleans Center for Clinical Research - Knoxville
815
mi
from 02139
Knoxville, TN
Click here to add this to my saved trials
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Status: Enrolling
Updated:  8/8/2013
Alamo Medical Research
1761
mi
from 02139
San Antonio, TX
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Status: Enrolling
Updated: 8/8/2013
Alamo Medical Research
1761
mi
from 02139
San Antonio, TX
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  9/24/2013
Mayo Clinic Hospital
2292
mi
from 02139
Phoenix, AZ
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 9/24/2013
Mayo Clinic Hospital
2292
mi
from 02139
Phoenix, AZ
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  9/24/2013
University of California Antiviral Research Center (AVRC)
2576
mi
from 02139
San Diego, CA
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 9/24/2013
University of California Antiviral Research Center (AVRC)
2576
mi
from 02139
San Diego, CA
Click here to add this to my saved trials